Harvard Dataverse. Replication Data for: Change in blood pressure, weight and other cardiovascular disease risk factors after switch from protease inhibitors to dolutegravir: Post-hoc analysis of the 48-week randomised 2SD trial

This is a week 48 dataset from an open-label, randomized, active-controlled, multi-center non-inferiority trial conducted by the University of Nairobi. The variables contained in this dataset from screening, enrolment, week 24 and week 48 include demographics, ARV history, medical history, concomitant medications, BP, weight, height, waist circumference, hip circumference, and laboratory investigations (HIV-1 RNA viral load, creatinine, hepatitis B surface antigen, fasting glucose, fasting lipid profile).